Compare First Trust NASDAQ Cybersecurity ETF (CIBR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust NASDAQ Cybersecurity ETF vs Sanofi SA — how do they compare? First Trust NASDAQ Cybersecurity ETF trades at $100.38, while Sanofi SA trades at $43.29 (market cap $104.57B). The key difference: Sanofi SA pays a 5.56% dividend while First Trust NASDAQ Cybersecurity ETF pays none, and First Trust NASDAQ Cybersecurity ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| CIBR | SNY | |
|---|---|---|
52-Week High | $100.60 | $52.34 |
52-Week Low | $60.74 | $41.33 |
Market Cap | — | $104.57B |
Sector | — | Health |
Enterprise Value | — | $124.48B |
Dividend Yield | — | 5.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CIBR, the First Trust Nasdaq Cybersecurity ETF, trades at $97.85, up 1.51% on the day, with a bullish technical signal from moving averages. The ETF has shown strong performance, reportedly outperforming the S&P 500 by three to one year-to-date as of June 5, 2026 (24/7 Wall Street). Recent news highlights institutional activity, including Bank of America reducing its stake while First Trust Advisors increased its position.
The outlook for CIBR is positive, driven by growing cybersecurity spending exceeding $300 billion in 2026 and AI-driven demand. Risks include high concentration in tech stocks and market volatility. Analyst sentiment is optimistic, with upgrades citing reasonable valuations and secular growth trends.
SNY trades at $43.46, up 1.33% today, with neutral technical signals and mixed analyst sentiment. The company reported strong Q2 2026 earnings beats and raised 2026 guidance, driven by Dupixent's performance. Recent approvals for MenQuadfi and Sarclisa injector provide growth catalysts, while pipeline setbacks like amlitelimab discontinuation present challenges. Valuation metrics show a P/E of 23.22 and P/S of 1.87, with improving profit margins from 12.55% in 2024 to 16.72% in 2025.
SNY offers steady dividend income with positive earnings momentum, though pipeline execution risks and competitive pressures remain concerns. The stock presents value for income-focused investors with upside potential from new drug approvals, but requires monitoring of CEO Garijo's strategic initiatives and Dupixent's long-term market position against biosimilar threats post-2031.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Trust NASDAQ Cybersecurity ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index includes securities of companies classified as cyber security companies. The fund is non-diversified.
Read more on CIBR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
